Key result
HK2 inhibitor ailanthone reduces myocardial injury and improves cardiac function in murine sepsis.
Why the study?
Elevated circulating lactate is a recognized prognostic biomarker in septic cardiomyopathy, but the mechanisms by which it exacerbates cardiac pathology are not fully understood.
Ailanthone attenuates myocardial injury and improves cardiac function in a murine model of septic cardiomyopathy by inhibiting HK2 and reducing MOF-mediated H4K16 lactylation-driven inflammation.
Answers are grounded in this paper and cite their sources.
Should not yet change septic cardiomyopathy practice; leaves open histone lactylation as hypothesis-generating therapeutic target.
BACKGROUND AND PURPOSE: Elevated circulating lactate is a recognized prognostic biomarker in septic cardiomyopathy (SCM), yet the mechanisms by which it exacerbates cardiac pathology are not fully understood. This study aims to investigate the role of histone lactylation as a novel epigenetic mechanism linking metabolic dysregulation to myocardial dysfunction in sepsis. EXPERIMENTAL APPROACH: The effects of lactate on lipopolysaccharide (LPS)-induced inflammation and apoptosis were assessed in cardiomyocytes in vitro. The underlying epigenetic mechanism was investigated using CUT&Tag. The role of MYST histone acetyltransferase 1 (MOF) as a lactyltransferase was determined through siRNA knockdown, co-immunoprecipitation and fluorescence co-localization assays. Furthermore, ailanthone (AIL), a specific hexokinase 2 (HK2) inhibitor identified through virtual screening, was evaluated for its therapeutic potential in a murine model of sepsis. KEY RESULTS: Lactate enhanced LPS-induced cardiomyocyte inflammation and apoptosis. Mechanistically, lactate upregulated histone H4 lysine 16 lactylation (H4K16la). This modification was enriched at the promoters of the CXCL8 and CCL2 genes to drive their transcriptional activation. We further identified MOF as a novel lactyltransferase directly catalysing H4K16la. In vivo, inhibition of HK2 with AIL attenuated myocardial injury and improved cardiac function in septic mice. CONCLUSION AND IMPLICATIONS: Our findings reveal a pathogenic axis wherein lactate-driven H4K16la, mediated by MOF, promotes inflammatory gene expression in SCM. This identifies the lactate-H4K16la pathway as a potential therapeutic target for mitigating septic cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2026) studied Septic cardiomyopathy. Ailanthone (AIL) was evaluated on Myocardial injury and cardiac function. Inhibition of hexokinase 2 with ailanthone attenuated myocardial injury and improved cardiac function in a murine model of sepsis by targeting the lactate-H4K16la pathway.
Synapse has enriched 10 related papers. Consider them for comparative context: